IQVIA (NYSE:IQV) Downgraded to “Hold” at StockNews.com

IQVIA (NYSE:IQV) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

A number of other equities analysts also recently issued reports on the company. Robert W. Baird upped their price target on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Truist Financial lifted their price target on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Evercore ISI boosted their target price on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, Barclays raised their price target on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $267.00.

IQVIA Stock Down 0.6 %

IQV stock opened at $234.79 on Friday. IQVIA has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company’s 50 day moving average price is $241.49 and its 200 day moving average price is $233.52. The firm has a market capitalization of $42.80 billion, a price-to-earnings ratio of 32.08, a PEG ratio of 2.25 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.22 earnings per share. On average, equities research analysts anticipate that IQVIA will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Institutional Trading of IQVIA

Hedge funds have recently modified their holdings of the business. Versant Capital Management Inc raised its position in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the 2nd quarter valued at about $27,000. Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter valued at about $29,000. Rise Advisors LLC purchased a new stake in IQVIA during the first quarter worth about $31,000. Finally, Riverview Trust Co acquired a new position in IQVIA during the first quarter worth about $32,000. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.